Data Sheet (Cat.No.T12745)

RO5263397

Chemical Properties



CAS No. : 1357266-05-7

Formula: C10H11FN2O

Molecular Weight: 194.21

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	RO5263397 is a TAAR1 specific agonist with oral activity that has been used in antidepressant studies. It has also been found to act as an inhibitor of the enzyme cyclooxygenase-2 (COX-2), which is involved in the synthesis of prostaglandins.
Targets(IC50)	Others
In vivo	Dosing at the mid-light phase (ZT6)(RO5263397) increased wake time at 0.3 and 1 mg/kg. RO5263397 ecreases NREM time in WT mice. RO5263397 (0.3 and 1.0mg/kg; p. o.; in OE mice) powerfully increases W time in OE mice for 5-6h. NREM sleep is suppressed for 4-6h and REM sleep is almost completely suppressed for 6h after all doses of RO5263397[3].

Solubility Information

Solubility	DMSO: 234 mg/mL (1204.88 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (25.75 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	5.1491 mL	25.7453 mL	51.4907 mL
5 mM	1.0298 mL	5.1491 mL	10.2981 mL
10 mM	0.5149 mL	2.5745 mL	5.1491 mL
50 mM	0.103 mL	0.5149 mL	1.0298 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Galley G, et al. Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.ACS Med Chem Lett. 2015 Dec 30;7(2):192-7.
Schwartz MD, et al. Trace Amine-Associated Receptor 1 Regulates Wakefulness and EEG Spectral Composition. Neuropsychopharmacology. 2017 May;42(6):1305-1314.
Espinoza S, et al. Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397.Front Pharmacol. 2018 Jun 21;9:645.